Jagadeesh Bayry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7419571/publications.pdf

Version: 2024-02-01

		207	797	27	7389	
297	14,289		60		106	
papers	citations		h-index		g-index	
309	309		309		19164	
all docs	docs citatio	ons	times ranked		citing authors	

#	Article	IF	CITATIONS
1	Restoration of established systemic inflammation and autoimmunity by Foxp3+ regulatory T cells. Cellular and Molecular Immunology, 2022, 19, 133-135.	4.8	О
2	The EHA Research Roadmap: Transfusion Medicine. HemaSphere, 2022, 6, e670.	1.2	2
3	Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition. Cancers, 2022, 14, 910.	1.7	5
4	SARS-CoV-2 Induces Cytokine Responses in Human Basophils. Frontiers in Immunology, 2022, 13, 838448.	2.2	11
5	IFN-Î ³ Induces PD-L1 Expression in Primed Human Basophils. Cells, 2022, 11, 801.	1.8	13
6	Basophils orchestrate kidney fibrosis. Cell Research, 2022, 32, 713-714.	5.7	1
7	IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans. Clinical and Experimental Immunology, 2021, 204, 258-266.	1.1	4
8	Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today, 2021, 36, 101051.	6.2	61
9	Small Molecule CCR4 Antagonists Protect Mice from Aspergillus Infection and Allergy. Biomolecules, 2021, 11, 351.	1.8	4
10	Species-Specific Immunological Reactivities Depend on the Cell-Wall Organization of the Two Aspergillus, Aspergillus fumigatus and A. flavus. Frontiers in Cellular and Infection Microbiology, 2021, 11, 643312.	1.8	7
11	Therapeutic Efficacy of Anti-Bestrophin Antibodies against Experimental Filariasis: Immunological, Immune-Informatics and Immune Simulation Investigations. Antibodies, 2021, 10, 14.	1.2	8
12	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 36-49.	0.8	8
13	CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis. Frontiers in Immunology, 2021, 12, 693974.	2.2	13
14	Vaccineâ€induced immune thrombotic thrombocytopenia: Consider IVIG batch in the treatment. Journal of Thrombosis and Haemostasis, 2021, 19, 1838-1839.	1.9	13
15	Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response. Autoimmunity Reviews, 2021, 20, 102850.	2.5	3
16	Structural and evolutionary exploration of the IL-3 family and its alpha subunit receptors. Amino Acids, 2021, 53, 1211-1227.	1.2	3
17	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respiratory Medicine, the, 2021, 9, 1467-1478.	5.2	84
18	Recent advances and prospects of hyaluronan as a multifunctional therapeutic system. Journal of Controlled Release, 2021, 336, 598-620.	4.8	59

#	Article	IF	Citations
19	Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants. Vaccines, 2021, 9, 1072.	2.1	19
20	Unraveling the mechanisms of IVIG immunotherapy in MIS-C. Cell Reports Medicine, 2021, 2, 100431.	3.3	7
21	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /O	verlock 10 4.3	0 Tf 50 662 T 1,430
22	Induction of antiviral and cell mediated immune responses significantly reduce viral load in an acute foot-and-mouth disease virus infection in cattle. Genomics, 2021, 113, 4254-4266.	1.3	2
23	Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nature Reviews Rheumatology, 2021, 17, 731-748.	3.5	126
24	Wnt- \hat{l}^2 -Catenin Signaling in Human Dendritic Cells Mediates Regulatory T-Cell Responses to Fungi via the PD-L1 Pathway. MBio, 2021, 12, e0282421.	1.8	18
25	In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein. Frontiers in Immunology, 2021, 12, 782506.	2.2	24
26	Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis. Clinical Reviews in Allergy and Immunology, 2020, 58, 213-228.	2.9	60
27	Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages. Human Vaccines and Immunotherapeutics, 2020, 16, 233-239.	1.4	5
28	For antigen-specific effector or Foxp3+ regulatory T cell fate, cyclin-dependent kinases hold the trump card. Cellular and Molecular Immunology, 2020, 17, 310-312.	4.8	1
29	Anti-lgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation. Cellular and Molecular Immunology, 2020, 17, 426-429.	4.8	8
30	Editorial: The Role of the Fungal Cell Wall in Host-Fungal Interactions. Frontiers in Cellular and Infection Microbiology, 2020, 10, 392.	1.8	2
31	Intravenous immunoglobulin immunotherapy for coronavirus diseaseâ€19 (COVIDâ€19). Clinical and Translational Immunology, 2020, 9, e1198.	1.7	37
32	The Role of RodA-Conserved Cysteine Residues in the Aspergillus fumigatus Conidial Surface Organization. Journal of Fungi (Basel, Switzerland), 2020, 6, 151.	1.5	9
33	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Frontiers in Immunology, 2020, 11, 810.	2.2	10
34	Progress and Challenges in the Use of MAP1LC3 as a Legitimate Marker for Measuring Dynamic Autophagy In Vivo. Cells, 2020, 9, 1321.	1.8	27
35	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy, 2020, 16, 2260-2266.	4.3	54
36	Differential Interactions of Serum and Bronchoalveolar Lavage Fluid Complement Proteins with Conidia of Airborne Fungal Pathogen Aspergillus fumigatus. Infection and Immunity, 2020, 88, .	1.0	9

#	Article	IF	CITATIONS
37	Stimulation with FITC-labeled antigens confers B cells with regulatory properties. Cellular Immunology, 2020, 355, 104151.	1.4	3
38	Autoimmune and inflammatory diseases following COVID-19. Nature Reviews Rheumatology, 2020, 16, 413-414.	3.5	298
39	Therapeutic normal IgG intravenous immunoglobulin activates Wnt- \hat{l}^2 -catenin pathway in dendritic cells. Communications Biology, 2020, 3, 96.	2.0	10
40	Potential of regulatory T-cell-based therapies in the management of severe COVID-19. European Respiratory Journal, 2020, 56, 2002182.	3.1	83
41	Regulatory T cells do not suppress rather activate human basophils by IL-3 and STAT5-dependent mechanisms. Oncolmmunology, 2020, 9, 1773193.	2.1	4
42	Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death and Disease, 2020, 11, 50.	2.7	30
43	Acid Stripping of Surface IgE Antibodies Bound to FcεRI Is Unsuitable for the Functional Assays That Require Long-Term Culture of Basophils and Entire Removal of Surface IgE. International Journal of Molecular Sciences, 2020, 21, 510.	1.8	6
44	Adjunct Immunotherapies for the Management of Severely III COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100016.	3.3	102
45	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. Frontiers in Immunology, 2020, 11, 393.	2.2	3
46	Aspergillus fumigatus Infection in Humans With STAT3-Deficiency Is Associated With Defective Interferon-Gamma and Th17 Responses. Frontiers in Immunology, 2020, 11, 38.	2.2	26
47	Mammary SLAMF3 Regulates Store-Operated Ca2+ Entry and Migration Through STIM1 in Breast Cancer Cells and Cell Lines. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, .	0.2	1
48	Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. Journal of Allergy and Clinical Immunology, 2019, 144, 524-535.e8.	1.5	36
49	Regulatory T Cells under the Mercy of Mitochondria. Cell Metabolism, 2019, 29, 243-245.	7.2	13
50	Current trends with FOXP3 (sup) + ($\log 7$) regulatory T cell immunotherapy to contest autoimmunity and inflammation. Immunotherapy, 2019, 11, 755-758.	1.0	5
51	Wuchereria bancrofti filaria activates human dendritic cells and polarizes T helper 1 andÂregulatory T cells via toll-like receptor 4. Communications Biology, 2019, 2, 169.	2.0	31
52	Assembly and disassembly of Aspergillus fumigatus conidial rodlets. Cell Surface, 2019, 5, 100023.	1.5	30
53	Intravenous Immunoglobulin Therapy Eliminates Candida albicans and Maintains Intestinal Homeostasis in a Murine Model of Dextran Sulfate Sodium-Induced Colitis. International Journal of Molecular Sciences, 2019, 20, 1473.	1.8	14
54	Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection?. Autoimmunity Reviews, 2019, 18, 632-633.	2.5	1

#	Article	IF	Citations
55	Intravenous immunoglobulin protects from experimental allergic bronchopulmonary aspergillosis via a sialylationâ€dependent mechanism. European Journal of Immunology, 2019, 49, 195-198.	1.6	23
56	Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies. Journal of Immunology, 2018, 200, 1957-1963.	0.4	26
57	Fungal melanin stimulates surfactant protein D–mediated opsonization of and host immune response to Aspergillus fumigatus spores. Journal of Biological Chemistry, 2018, 293, 4901-4912.	1.6	36
58	Induction of human dendritic cell maturation by na \tilde{A} -ve and memory B-cell subsets requires different activation stimuli. Cellular and Molecular Immunology, 2018, 15, 1074-1076.	4.8	2
59	Immunotherapy as an Option for Cancer Treatment. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 89-96.	1.0	19
60	The use of databases, data mining and immunoinformatics in vaccinology: where are we?. Expert Opinion on Drug Discovery, 2018, 13, 117-130.	2.5	24
61	Signaling lymphocytic activation molecules Slam and cancers: friends or foes?. Oncotarget, 2018, 9, 16248-16262.	0.8	14
62	Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1. Frontiers in Immunology, 2018, 9, 2570.	2.2	39
63	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer, 2018, 143, 3008-3018.	2.3	16
64	Kill †Em All: Efgartigimod Immunotherapy for Autoimmune Diseases. Trends in Pharmacological Sciences, 2018, 39, 919-922.	4.0	11
65	Multimerized IgG1 Fc molecule as an anti-inflammatory agent. Nature Reviews Rheumatology, 2018, 14, 390-392.	3.5	7
66	Regulatory T cells induce activation rather than suppression of human basophils. Science Immunology, $2018, 3, \ldots$	5.6	38
67	Role of Hydrophobins in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 2.	1.5	93
68	Indian researchers must resist predatory open-access journals. Nature, 2018, 563, 35-35.	13.7	3
69	Catalytic antibodies in patients with systemic lupus erythematosus. European Journal of Rheumatology, 2018, 5, 173-178.	1.3	6
70	Human basophils may not undergo modulation by DC-SIGN and mannose receptor–targeting immunotherapies due to absence of receptors. Journal of Allergy and Clinical Immunology, 2017, 139, 1403-1404.e1.	1.5	5
71	Demystification of enigma on antigen-presenting cell features of human basophils: data from secondary lymphoid organs. Haematologica, 2017, 102, e233-e237.	1.7	11
72	Emerging and Re-emerging Infectious Diseases of Livestock. , 2017, , .		9

#	Article	IF	Citations
73	Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. Journal of Neuroinflammation, 2017, 14, 58.	3.1	23
74	The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them. Cellular Microbiology, 2017, 19, e12746.	1.1	37
75	Aspergillus fumigatus Cell Wall α-(1,3)-Glucan Stimulates Regulatory T-Cell Polarization by Inducing PD-L1 Expression on Human Dendritic Cells. Journal of Infectious Diseases, 2017, 216, 1281-1294.	1.9	81
76	Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin. Trends in Immunology, 2017, 38, 789-792.	2.9	35
77	Harnessing the regulators to enhance viral vaccine efficacy. Future Medicinal Chemistry, 2017, 9, 1319-1321.	1.1	1
78	IVIG-mediated effector functions in autoimmune and inflammatory diseases. International Immunology, 2017, 29, 491-498.	1.8	204
79	In Silico Adjuvant Design and Validation. Methods in Molecular Biology, 2017, 1494, 107-125.	0.4	4
80	Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN. Frontiers in Immunology, 2017, 8, 275.	2.2	25
81	CCR4 is a determinant of melanoma brain metastasis. Oncotarget, 2017, 8, 31079-31091.	0.8	65
82	Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4+ T Cell Responses. Molecules, 2016, 21, 912.	1.7	15
83	The Homophilic Domain – An Immunological Archetype. Frontiers in Immunology, 2016, 7, 106.	2.2	7
84	IL- $1\hat{l}^2$, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis. Frontiers in Immunology, 2016, 7, 465.	2.2	16
85	IL-26: An Emerging Proinflammatory Member of the IL-10 Cytokine Family with Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses. PLoS Pathogens, 2016, 12, e1005624.	2.1	58
86	Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this †hard nutâ€. Immunotherapy, 2016, 8, 99-101.	1.0	1
87	Repressing Immunity in Autoimmune Disease. New England Journal of Medicine, 2016, 374, 2090-2092.	13.9	9
88	Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease. Drug Discovery Today, 2016, 21, 1850-1857.	3.2	48
89	Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. Scientific Reports, 2016, 6, 24193.	1.6	54
90	Tackling Difficult Staphylococcus aureus Infections: Antibodies Show the Way. Cell Host and Microbe, 2016, 20, 555-557.	5.1	25

#	Article	IF	Citations
91	Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Scientific Reports, 2016, 6, 19592.	1.6	19
92	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Research, 2016, 76, 4100-4112.	0.4	42
93	Lupus pathogenesis: role of IgE autoantibodies. Cell Research, 2016, 26, 271-272.	5.7	14
94	Orientation de la réponse immune par les basophiles. Revue Francaise D'allergologie, 2016, 56, 117-119.	0.1	0
95	European Viscum album: a potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence. RSC Advances, 2016, 6, 23837-23857.	1.7	44
96	Regulatory T Cell Immunotherapy for Type 1 Diabetes: A Step Closer to Success?. Cell Metabolism, 2016, 23, 231-233.	7.2	19
97	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	1.7	67
98	Relationship between natural and heme-mediated antibody polyreactivity. Biochemical and Biophysical Research Communications, 2016, 472, 281-286.	1.0	6
99	Impaired regulatory T cell function in autoimmune diseases: are microRNAs the culprits?. Cellular and Molecular Immunology, 2016, 13, 135-137.	4.8	6
100	Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors. Immunology Letters, 2016, 169, 93-97.	1.1	1
101	Cross-presentation of antigens by dendritic cells: role of autophagy. Oncotarget, 2015, 6, 28527-28528.	0.8	15
102	IVIg for relapsing–remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences, 2015, 36, 419-421.	4.0	15
103	lgE response to two new allergen proteins of Solanum melongena L. (eggplant). Immunology Letters, 2015, 168, 268-270.	1.1	2
104	Intravenous immunoglobulin as clinical immune-modulating therapy. Cmaj, 2015, 187, 257-264.	0.9	74
105	Molecular and immunological biomarkers to predict IVIg response. Trends in Molecular Medicine, 2015, 21, 145-147.	3.5	31
106	Basophils in autoimmune and inflammatory diseases. Nature Reviews Rheumatology, 2015, 11, 129-131.	3.5	22
107	Mechanism and Functional Implications of the Heme-Induced Binding Promiscuity of IgE. Biochemistry, 2015, 54, 2061-2072.	1.2	13
108	Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cellular and Molecular Immunology, 2015, 12, 650-652.	4.8	33

#	Article	IF	Citations
109	B cells drive Th2 responses by instructing human dendritic cell maturation. Oncolmmunology, 2015, 4, e1005508.	2.1	20
110	Basophils are inept at promoting human Th17 responses. Human Immunology, 2015, 76, 176-180.	1.2	11
111	Inhibition of Programmed Death 1 Ligand 1 on Dendritic Cells Enhances Mycobacterium-Mediated Interferon (IFN-Â) Production Without Modulating the Frequencies of IFN-Â-Producing CD4+ T Cells. Journal of Infectious Diseases, 2015, 211, 1027-1029.	1.9	9
112	The protective role of immunoglobulins in fungal infections and inflammation. Seminars in Immunopathology, 2015, 37, 187-197.	2.8	37
113	Viscum album-Mediated COX-2 Inhibition Implicates Destabilization of COX-2 mRNA. PLoS ONE, 2015, 10, e0114965.	1.1	18
114	Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination. PLoS ONE, 2015, 10, e0131364.	1.1	11
115	Defective functions of polymorphonuclear neutrophils in patients with common variable immunodeficiency. Immunologic Research, 2014, 60, 69-76.	1.3	18
116	Autoantibodies in Therapeutic Preparations of Human Intravenous Immunoglobulin (IVIg). , 2014, , 305-310.		0
117	Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients. Immunologic Research, 2014, 60, 320-329.	1.3	53
118	Interferonâ€Î± Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et al. Arthritis and Rheumatology, 2014, 66, 2308-2309.	2.9	2
119	Mediation of T-Helper 17 Responses to Schistosomes by Dendritic Cells but Not Basophils. Journal of Infectious Diseases, 2014, 209, 2019-2021.	1.9	4
120	Selective inhibition of IFNG-induced autophagy by <i>Mir155</i> - and <i>Mir31</i> - responsive WNT5A and SHH signaling. Autophagy, 2014, 10, 311-330.	4.3	72
121	Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. European Journal of Immunology, 2014, 44, 2059-2063.	1.6	43
122	Clinical and Autoimmune Profile of Scleroderma Patients from Western India. International Journal of Rheumatology, 2014, 2014, 1-6.	0.9	30
123	Intravenous immunoglobulin and immune response. Clinical and Experimental Immunology, 2014, 178, 94-96.	1.1	15
124	GM-CSF along with IL-4 but not alone is indispensable for the differentiation of human dendritic cells from monocytes. Journal of Allergy and Clinical Immunology, 2014, 133, 1500-1502.e1.	1.5	9
125	Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy. VirusDisease, 2014, 25, 18-25.	1.0	24
126	IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Reviews Immunology, 2014, 14, 349-349.	10.6	68

#	Article	IF	Citations
127	T Cell–Derived IL-22 Amplifies IL-1β–Driven Inflammation in Human Adipose Tissue: Relevance to Obesity and Type 2 Diabetes. Diabetes, 2014, 63, 1966-1977.	0.3	197
128	Japanese encephalitis virus expands regulatory TÂcells by increasing the expression of PD‣1 on dendritic cells. European Journal of Immunology, 2014, 44, 1363-1374.	1.6	30
129	Natural Autoantibodies to $Fc\hat{l}^3$ Receptors in Intravenous Immunoglobulins. Journal of Clinical Immunology, 2014, 34, 4-11.	2.0	21
130	Re: Kaiser: Emerging Therapies for Neovascular Age-related Macular Degeneration: Drugs in the Pipeline (Ophthalmology 2013;120:S11-S15). Ophthalmology, 2014, 121, e21-e22.	2.5	0
131	Surface Structure Characterization of Aspergillus fumigatus Conidia Mutated in the Melanin Synthesis Pathway and Their Human Cellular Immune Response. Infection and Immunity, 2014, 82, 3141-3153.	1.0	113
132	Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends in Pharmacological Sciences, 2014, 35, 163-165.	4.0	36
133	Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies. Veterinary Microbiology, 2014, 169, 233-235.	0.8	20
134	Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nature Communications, 2014, 5, 4092.	5.8	60
135	Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Scientific Reports, 2014, 4, 5672.	1.6	31
136	Regulation of Human Dendritic Cell Functions by Natural Anti-CD40 Antibodies. Methods in Molecular Biology, 2014, 1155, 47-54.	0.4	2
137	Inhibitory Effect of IVIG on IL-17 Production by Th17 Cells is Independent of Anti-IL-17 Antibodies in the Immunoglobulin Preparations. Journal of Clinical Immunology, 2013, 33, 62-66.	2.0	40
138	A role for IL-17 in age-related macular degeneration. Nature Reviews Immunology, 2013, 13, 701-701.	10.6	14
139	Unraveling the Nanoscale Surface Properties of Chitin Synthase Mutants ofÂAspergillus fumigatus and Their Biological Implications. Biophysical Journal, 2013, 105, 320-327.	0.2	19
140	Mycobacterium tuberculosis Cell Wall–Associated Rv3812 Protein Induces Strong Dendritic Cell–Mediated Interferon γ Responses and Exhibits Vaccine Potential. Journal of Infectious Diseases, 2013, 208, 1034-1036.	1.9	8
141	Emerging viral diseases of livestock in the developing world. Indian Journal of Virology: an Official Organ of Indian Virological Society, 2013, 24, 291-294.	0.7	11
142	Open-access boom in developing nations. Nature, 2013, 497, 40-40.	13.7	11
143	Sonic hedgehog-Dependent Induction of MicroRNA 31 and MicroRNA 150 Regulates <i>Mycobacterium bovis</i> BCG-Driven Toll-Like Receptor 2 Signaling. Molecular and Cellular Biology, 2013, 33, 543-556.	1.1	63
144	Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells. Journal of Allergy and Clinical Immunology, 2013, 131, 1255-1257.e1.	1.5	9

#	Article	IF	CITATIONS
145	Human basophils lack the capacity to drive memory CD4+ T cells toward the IL-22 response. Journal of Allergy and Clinical Immunology, 2013, 132, 1457-1458.e1.	1.5	7
146	Th17 cells, pathogenic or not? TGF- \hat{l}^2 3 imposes the embargo. Cellular and Molecular Immunology, 2013, 10, 101-102.	4.8	13
147	Therapeutic factor VIII does not trigger <scp>TLR</scp> 1.2 and <scp>TLR</scp> 2.6 signalling <i>in vitro</i> . Haemophilia, 2013, 19, 399-402.	1.0	11
148	Dual Role of CpGâ€Stimulated B Cells in the Regulation of Dendritic Cells: Comment on the Article by Berggren et al. Arthritis and Rheumatism, 2013, 65, 2215-2216.	6.7	2
149	Circulating human basophils lack the features of professional antigen presenting cells. Scientific Reports, 2013, 3, 1188.	1.6	48
150	Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis. Journal of Immunology, 2013, 190, 4535-4541.	0.4	56
151	Lowâ€dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic PancO2 model of pancreatic cancer. International Journal of Cancer, 2013, 133, 98-107.	2.3	138
152	Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncolmmunology, 2013, 2, e25736.	2.1	24
153	Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2–dependent prostaglandin E2 in human dendritic cells. Blood, 2013, 122, 1419-1427.	0.6	149
154	Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous Immunoglobulin Exert Potent Antibody-Dependent Cellular Cytotoxicity. PLoS ONE, 2013, 8, e69390.	1.1	18
155	Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease. Journal of Rheumatology, 2012, 39, 450-451.	1.0	48
156	Myeloid Dendritic Cell Dysfunction During Primary HIV-1 Infection Is Independent of Interaction With gp120. Journal of Infectious Diseases, 2012, 205, 1893-1895.	1.9	4
157	Impact of gp120 on Dendritic Cell-Derived Chemokines: Relevance for the Efficacy of gp120-Based Vaccines for HIV-1. Vaccine Journal, 2012, 19, 1335-1336.	3.2	3
158	Mycobacterium tuberculosis Promotes Regulatory T-Cell Expansion via Induction of Programmed Death-1 Ligand 1 (PD-L1, CD274) on Dendritic Cells. Journal of Infectious Diseases, 2012, 205, 694-696.	1.9	54
159	Chemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseases. Immunotherapy, 2012, 4, 9-12.	1.0	2
160	More credit due to India's scientists. Nature, 2012, 484, 167-167.	13.7	0
161	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncolmmunology, 2012, 1, 326-333.	2.1	95
162	Effect of CC chemokine receptor 4 antagonism on the evolution of experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2412-E2413.	3.3	9

#	Article	IF	Citations
163	Hydrophobins—Unique Fungal Proteins. PLoS Pathogens, 2012, 8, e1002700.	2.1	252
164	Toll-like receptor-2 ligand lipomannan from Mycobacterium tuberculosis does not stimulate inflammatory cytokines in dendritic cells. Aids, 2012, 26, 1182-1184.	1.0	2
165	Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood, 2012, 120, 1237-1245.	0.6	79
166	Regulation of human dendritic cells by B cells depends on the signals they receive. Blood, 2012, 119, 3863-3864.	0.6	17
167	Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: Role of lipid accumulation. Journal of Autoimmunity, 2012, 39, 168-172.	3.0	18
168	Th17 Cells. American Journal of Pathology, 2012, 181, 8-18.	1.9	505
169	Natural IgM in Immune Equilibrium and Harnessing Their Therapeutic Potential. Journal of Immunology, 2012, 188, 939-945.	0.4	126
170	Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. Journal of Allergy and Clinical Immunology, 2011, 127, 823-830.e7.	1.5	135
171	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. Journal of Autoimmunity, 2011, 36, 9-15.	3.0	67
172	New horizons in natural TNF-α antagonist research. Trends in Molecular Medicine, 2011, 17, 538-540.	3.5	8
173	CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. Vaccine, 2011, 29, 2649-2652.	1.7	10
174	Viscum album Exerts Anti-Inflammatory Effect by Selectively Inhibiting Cytokine-Induced Expression of Cyclooxygenase-2. PLoS ONE, 2011, 6, e26312.	1.1	46
175	A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms. PLoS ONE, 2011, 6, e26469.	1.1	38
176	Enhancement of the Affinity of Glucocorticoid Receptors as a Mechanism Underlying the Steroid-sparing Effect of Intravenous Immunoglobulin: Figure 1 Journal of Rheumatology, 2011, 38, 2275-2275.	1.0	5
177	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 2011, 117, 2257-2264.	0.6	38
178	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood, 2011, 118, 4853-4862.	0.6	144
179	Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clinical and Experimental Immunology, 2011, 164, 2-5.	1.1	127
180	Bortezomib delays the onset of factorÂVIII inhibitors in experimental hemophiliaÂA, but fails to eliminate established antiâ€factorÂVIII IgGâ€producing cells. Journal of Thrombosis and Haemostasis, 2011, 9, 719-728.	1.9	12

#	Article	IF	CITATIONS
181	World Rabies Day: a prime role for veterinarians in rabies control. Nature Reviews Microbiology, 2011, 9, 75-75.	13.6	46
182	Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discovery Today, 2011, 16, 1061-1068.	3.2	59
183	Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmunity Reviews, 2011, 10, 809-810.	2.5	55
184	B cells are resistant to immunomodulation by â€~IVIg-educated' dendritic cells. Autoimmunity Reviews, 2011, 11, 154-156.	2.5	22
185	Intravenous immunoglobulin therapy in rheumatic diseases. Nature Reviews Rheumatology, 2011, 7, 349-359.	3.5	115
186	Cooperative Regulation of NOTCH1 Protein-Phosphatidylinositol 3-Kinase (PI3K) Signaling by NOD1, NOD2, and TLR2 Receptors Renders Enhanced Refractoriness to Transforming Growth Factor- \hat{l}^2 (TGF- \hat{l}^2)-or Cytotoxic T-lymphocyte Antigen 4 (CTLA-4)-mediated Impairment of Human Dendritic Cell Maturation. Journal of Biological Chemistry, 2011, 286, 31347-31360.	1.6	20
187	Indian Science: Steps to Excellence. Science, 2011, 331, 29-30.	6.0	1
188	Cutting Edge: Intravenous Ig Inhibits Invariant NKT Cell-Mediated Allergic Airway Inflammation through Fcl ³ RIIIA-Dependent Mechanisms. Journal of Immunology, 2011, 186, 3289-3293.	0.4	35
189	Induction of heme oxygenase-1 in factor VIII–deficient mice reduces the immune response to therapeutic factor VIII. Blood, 2010, 115, 2682-2685.	0.6	28
190	Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells. Journal of Clinical Immunology, 2010, 30, 4-8.	2.0	63
191	Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmunity Reviews, 2010, 9, 441-448.	2.5	90
192	Contribution of myeloid dendritic cells to type I interferon-induced cytokines and chemokines. Arthritis and Rheumatism, 2010, 62, n/a - n/a .	6.7	4
193	Members of protein Oâ€mannosyltransferase family in <i>Aspergillus fumigatus</i> differentially affect growth, morphogenesis and viability. Molecular Microbiology, 2010, 76, 1205-1221.	1.2	81
194	Metrics: journal's impact factor skewed by a single paper. Nature, 2010, 466, 179-179.	13.7	33
195	Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation. Thrombosis and Haemostasis, 2010, 104, 1093-1098.	1.8	8
196	PE_PGRS Antigens of <i>Mycobacterium tuberculosis </i> Induce Maturation and Activation of Human Dendritic Cells. Journal of Immunology, 2010, 184, 3495-3504.	0.4	107
197	Basophils and Nephritis in Lupus. New England Journal of Medicine, 2010, 363, 1080-1082.	13.9	27
198	Src Homology 3-interacting Domain of Rv1917c of Mycobacterium tuberculosis Induces Selective Maturation of Human Dendritic Cells by Regulating PI3K-MAPK-NF-ÎB Signaling and Drives Th2 Immune Responses. Journal of Biological Chemistry, 2010, 285, 36511-36522.	1.6	102

#	Article	IF	CITATIONS
199	Autoimmunity as a Predisposition for Infectious Diseases. PLoS Pathogens, 2010, 6, e1001077.	2.1	45
200	μ-Opioid Receptor Is Induced by IL-13 within Lymph Nodes from Patients with Sézary Syndrome. Journal of Investigative Dermatology, 2010, 130, 1337-1344.	0.3	20
201	Basophils as antigen presenting cells. Trends in Immunology, 2010, 31, 45-48.	2.9	25
202	TL1A in the inflammatory network in autoimmune diseases. Nature Reviews Rheumatology, 2010, 6, 67-68.	3.5	32
203	Dendritic Cells in Autoimmune Diseases. Open Arthritis Journal, 2010, 3, 1-7.	0.0	6
204	Dendritic Cells in Autoimmune Diseases. Open Arthritis Journal, 2010, 3, 1-7.	0.0	2
205	Toward the Discovery of Vaccine Adjuvants: Coupling In Silico Screening and In Vitro Analysis of Antagonist Binding to Human and Mouse CCR4 Receptors. PLoS ONE, 2009, 4, e8084.	1.1	51
206	CTLA-4: a key protein in autoimmunity. Nature Reviews Rheumatology, 2009, 5, 244-245.	3.5	24
207	DC-SIGN and $\hat{l}\pm 2,6$ -sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, E24; author reply E25.	3.3	68
208	B Lymphocytes from Patients with Tuberculosis Exhibit Hampered Antigenâ€Specific Responses with Concomitant Overexpression of Interleukinâ€8. Journal of Infectious Diseases, 2009, 200, 481-482.	1.9	7
209	Parameters that influence the prediction of epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, E129; author reply E130.	3.3	1
210	Factor VIIIâ€hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters, 2009, 583, 2565-2572.	1.3	18
211	CD4+CD25+ regulatory T cells modulate human dendritic cell chemokines via multiple mechanisms: Comment on the article by Kolar et al. Arthritis and Rheumatism, 2009, 60, 2848-2849.	6.7	6
212	6th International Immunoglobulin Symposium: Poster presentations. Clinical and Experimental Immunology, 2009, 158, 60-67.	1.1	12
213	Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature, 2009, 460, 1117-1121.	13.7	666
214	Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin. Nature Reviews Drug Discovery, 2009, 8, 594-594.	21.5	4
215	Reasons to include viruses in the tree of life. Nature Reviews Microbiology, 2009, 7, 615-615.	13.6	30
216	Splenic marginal zone antigenâ€presenting cells are critical for the primary alloâ€immune response to therapeutic factor VIII in hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 1816-1823.	1.9	60

#	Article	IF	Citations
217	Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends in Pharmacological Sciences, 2009, 30, 287-295.	4.0	99
218	Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: A perspective. Vaccine, 2009, 27, 2199-2201.	1.7	9
219	Simultaneous engagement of $Fc\hat{l}^3$ IIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Molecular Immunology, 2009, 47, 123-130.	1.0	15
220	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297.	1.0	6
221	Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discovery Today: Therapeutic Strategies, 2009, 6, 5-11.	0.5	2
222	Surveillance of Antigen-Presenting Cells by CD4+CD25+ Regulatory T Cells in Autoimmunity. American Journal of Pathology, 2009, 174, 1575-1587.	1.9	123
223	Immunointervention for patients with HIV and tuberculosis. Lancet Infectious Diseases, The, 2009, 9, 332-333.	4.6	1
224	Immunotherapy of viral infections. Immunotherapy, 2009, 1, 691-711.	1.0	11
225	Journal club. Nature, 2008, 456, 285-285.	13.7	0
226	Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants?. Nature Reviews Immunology, 2008, 8, 1-2.	10.6	11
227	From 'perfect mix' to 'potion magique' â€" regulatory T cells and anti-inflammatory cytokines as adjuvant targets. Nature Reviews Microbiology, 2008, 6, 88-88.	13.6	12
228	Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum albumas complimentary therapy in cancer. BMC Cancer, 2008, 8, 161.	1.1	37
229	Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmunity Reviews, 2008, 7, 440-444.	2.5	7 3
230	Modulation of human dendritic cell maturation and function by natural IgG antibodies. Autoimmunity Reviews, 2008, 7, 487-490.	2.5	23
231	Modulation of the cellular immune system by intravenous immunoglobulin. Trends in Immunology, 2008, 29, 608-615.	2.9	186
232	Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica, 2008, 93, 83-89.	1.7	34
233	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. Journal of Immunology, 2008, 181, 1609-1615.	0.4	18
234	In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10221-10226.	3.3	126

#	Article	IF	Citations
235	Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia. Journal of Immunology, 2008, 180, 7714-7720.	0.4	45
236	The Antiinflammatory IgG. New England Journal of Medicine, 2008, 359, 307-309.	13.9	72
237	Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 2008, 111, 715-722.	0.6	252
238	Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood, 2008, 112, 240-249.	0.6	80
239	Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica, 2007, 92, 1423-1426.	1.7	40
240	Human Dendritic Cells Acquire a Semimature Phenotype and Lymph Node Homing Potential through Interaction with CD4+CD25+ Regulatory T Cells. Journal of Immunology, 2007, 178, 4184-4193.	0.4	79
241	Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?. Nephrology Dialysis Transplantation, 2007, 22, 1301-1304.	0.4	8
242	Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. Expert Review of Clinical Immunology, 2007, 3, 677-681.	1.3	6
243	Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nature Clinical Practice Rheumatology, 2007, 3, 262-272.	3.2	94
244	VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood, 2007, 109, 610-612.	0.6	179
245	A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8965-8970.	3.3	110
246	Shortage of human intravenous immunoglobulinâ€"reasons and possible solutions. Nature Clinical Practice Neurology, 2007, 3, 120-121.	2.7	71
247	Do activated human dendritic cells diminish the suppressive functions of CD4+,CD25+ regulatory T cells? Comment on the article by van Amelsfort et al. Arthritis and Rheumatism, 2007, 56, 3874-3876.	6.7	4
248	Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discovery Today, 2007, 12, 548-552.	3.2	59
249	Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases: A Mechanistic Perspective. Annals of the New York Academy of Sciences, 2007, 1110, 497-506.	1.8	32
250	Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action. Journal of Clinical Immunology, 2007, 27, 233-245.	2.0	240
251	Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Letters, 2006, 243, 32-37.	3.2	37
252	Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms. International Immunopharmacology, 2006, 6, 528-534.	1.7	70

#	Article	IF	CITATIONS
253	Interaction of foot-and-mouth disease virus with dendritic cells. Trends in Microbiology, 2006, 14, 346-347.	3.5	5
254	Modelling infectious diseases: viral complexity. Nature Reviews Microbiology, 2006, 4, 637-637.	13.6	1
255	Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes. Immunology Letters, 2006, 107, 58-62.	1.1	8
256	Molecular Mechanisms Underlying the Immunomodulatory Effects of Mistletoe (Viscum album L.) Extracts Iscador. Arzneimittelforschung, 2006, 56, 461-466.	0.5	27
257	Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII. Journal of Immunology, 2006, 177, 1355-1363.	0.4	45
258	Intravenous Immunoglobulin and Dendritic Cells. Clinical Reviews in Allergy and Immunology, 2005, 29, 201-206.	2.9	13
259	Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. Journal of Neurology, 2005, 252, i1-i6.	1.8	24
260	Immunoglobulin-Dependent Regulation of Dendritic Cells in the Context of Autoimmune Responses. Transfusion Medicine and Hemotherapy, 2005, 32, 369-372.	0.7	1
261	Modulation of Dendritic Cell Maturation and Function by B Lymphocytes. Journal of Immunology, 2005, 175, 15-20.	0.4	72
262	Emergence of a Nephropathogenic Avian Infectious Bronchitis Virus with a Novel Genotype in India. Journal of Clinical Microbiology, 2005, 43, 916-918.	1.8	54
263	Natural autoantibodies: immune homeostasis and therapeutic intervention. Expert Review of Clinical Immunology, 2005, 1, 213-222.	1.3	5
264	Common variable immunodeficiency: the immune system in chaos. Trends in Molecular Medicine, 2005, 11, 370-376.	3.5	80
265	Is RNA interference feasible for the control of foot-and-mouth disease outbreaks?. Trends in Immunology, 2005, 26, 238-239.	2.9	9
266	Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. American Journal of Medicine, 2005, 118, 1439-1440.	0.6	24
267	High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4109-4113.	3.3	110
268	Natural antibodies sustain differentiation and maturation of human dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14210-14215.	3.3	100
269	Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. International Immunology, 2004, 16, 517-524.	1.8	33
270	Cutting Edge: Human CD4+CD25+ T Cells Restrain the Maturation and Antigen-Presenting Function of Dendritic Cells. Journal of Immunology, 2004, 172, 4676-4680.	0.4	415

#	Article	IF	CITATIONS
271	Dendritic cells and autoimmunity. Autoimmunity Reviews, 2004, 3, 183-187.	2.5	38
272	Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?. Trends in Pharmacological Sciences, 2004, 25, 306-310.	4.0	100
273	Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood, 2004, 104, 2441-2443.	0.6	124
274	Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurological Sciences, 2003, 24, s217-s221.	0.9	57
275	Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-? present in serum from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 3497-3502.	6.7	103
276	Natural Autoantibodies as Tools to Predict the Outcome of Immune Response?. Scandinavian Journal of Immunology, 2003, 58, 285-289.	1.3	52
277	Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfusion Clinique Et Biologique, 2003, 10, 165-169.	0.2	85
278	Autoantibodies to factor VIII with catalytic activity. Autoimmunity Reviews, 2003, 2, 30-35.	2.5	11
279	Intravenous Immunoglobulin for Infectious Diseases: Tailorâ€Made or Universal?. Journal of Infectious Diseases, 2003, 188, 1610-1610.	1.9	9
280	Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood, 2003, 101, 758-765.	0.6	280
281	Biological Functions of Catalytic Antibodies. Transfusion Medicine and Hemotherapy, 2003, 30, 264-267.	0.7	0
282	Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A. Thrombosis and Haemostasis, 2003, 90, 813-822.	1.8	15
283	The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. New England Journal of Medicine, 2002, 346, 662-667.	13.9	107
284	Immune Responses of Sheep to Quadrivalent Double Emulsion Foot-and-Mouth Disease Vaccines: Rate of Development of Immunity and Variations among Other Ruminants. Journal of Clinical Microbiology, 2002, 40, 4367-4371.	1.8	28
285	Autoantibodies to factor VIII. Autoimmunity Reviews, 2002, 1, 105-110.	2.5	15
286	Integrity of GH-loop of foot-and-mouth disease virus during virus inactivation: detection by epitope specific antibodies. Vaccine, 2002, 20, 1163-1168.	1.7	12
287	Immune responses of goats against foot-and-mouth disease quadrivalent vaccine: comparison of double oil emulsion and aluminium hydroxide gel vaccines in eliciting immunity. Vaccine, 2002, 20, 2781-2789.	1.7	52
288	Induction of Apoptosis of Endothelial Cells by Viscum album: A Role for Anti-Tumoral Properties of Mistletoe Lectins. Molecular Medicine, 2002, 8, 600-606.	1.9	31

#	Article	lF	CITATIONS
289	Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A. Journal of Immunological Methods, 2002, 269, 251-256.	0.6	8
290	Early antibody responses of cattle for foot-and-mouth disease quadrivalent double oil emulsion vaccine. Veterinary Microbiology, 2002, 87, 103-109.	0.8	12
291	Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia, 2002, 8, 273-279.	1.0	24
292	The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A. Haemophilia, 2002, 8, 55-59.	1.0	2
293	Immunomodulation of Autoimmunity by Intravenous Immunoglobulin through Interaction with Immune Networks. Vox Sanguinis, 2002, 83, 49-52.	0.7	6
294	Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Molecular Medicine, 2002, 8, 600-6.	1.9	12
295	Foot and Mouth Disease: a Revised Policy Is Required. Journal of Clinical Microbiology, 2001, 39, 3808-3808.	1.8	3
296	Immuno affinity purification of foot and mouth disease virus type specific antibodies using recombinant protein adsorbed to polystyrene wells. Journal of Virological Methods, 1999, 81, 21-30.	1.0	4
297	Protective Immune Response to 16 kDa Immunoreactive Recombinant Protein Encoding the Câ€Terminal VP1 Portion of Foot and Mouth Disease Virus Type Asia 1. Microbiology and Immunology, 1999, 43, 765-771.	0.7	14